Skip to main content
Shandong Sito Bio-technology Co., Ltd. logo

Shandong Sito Bio-technology Co., Ltd. — Investor Relations & Filings

Ticker · 300583 ISIN · CNE100002F36 LEI · 836800ENMRCW06CD2U25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,388 across all filing types
Latest filing 2025-12-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300583

About Shandong Sito Bio-technology Co., Ltd.

https://www.sitobiotech.com

Shandong Sito Bio-technology Co., Ltd. specializes in the research, development, and production of steroid hormone intermediates and active pharmaceutical ingredients (APIs). The company utilizes biological fermentation technology to transform phytosterols into critical precursors, including 4-AD, ADD, and 9-OH-AD. These materials are fundamental components for the synthesis of glucocorticoids, sex hormones, and progestogens. By integrating microbial strain engineering with large-scale industrial fermentation, the company provides high-purity raw materials for global drug manufacturing. Its operations emphasize green chemistry and sustainable production methods, maintaining a comprehensive supply chain that spans from raw material processing to the delivery of specialized chemical intermediates.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于山东赛托生物科技股份有限公司变更部分募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Guojin Securities Co., Ltd. regarding the verification opinion on the change of part of the raised funds investment projects of Shandong Saito Biotechnology Co., Ltd. It includes extensive information about the original and new investment projects, investment amounts, reasons for changes, project feasibility, expected returns, risks, and regulatory compliance. The document references regulatory approvals, detailed financial figures, project descriptions, and compliance with listing rules and supervisory guidelines. It is not a brief announcement but a comprehensive verification report related to fundraising and investment project changes. This fits the category of Capital/Financing Update (CAP), as it deals with changes in the use of raised funds and investment projects, including regulatory and supervisory opinions. The document length (7964 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2025-12-05 Chinese
山东赛托生物科技股份有限公司关于召开2025年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders for Shandong Sitobiotech Co., Ltd. It includes details about the meeting time, location, agenda items, voting procedures, and registration instructions. The document does not contain financial statements or results but is an announcement informing shareholders about the meeting and how to participate. The document length is 3800 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-05 Chinese
关于变更部分募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change in the use of previously raised funds from a specific stock issuance. It details the original investment project, the reasons for adjustment, the new investment project, and the expected benefits and risks. It references approvals from regulatory bodies and the company's board resolutions. The document is focused on changes to capital allocation and investment projects funded by raised capital. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or legal proceeding. It is a detailed announcement about capital use and investment project changes, which fits the definition of a Capital/Financing Update (CAP). The document length is 7,810 characters, which is substantive and not a mere announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2025-12-05 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Shandong Saito Biotechnology Co., Ltd. It details decisions made at the 11th meeting of the 4th board of directors, including changes to fundraising investment projects, authorization for opening a special fundraising account, approval of a remuneration management system for directors and senior management, and the proposal to convene a second extraordinary shareholders meeting in 2025. The document includes voting results and references to further disclosures on the company's information disclosure website. It is not a full financial report, earnings release, or regulatory certification, but rather an official announcement of board decisions and management-related resolutions. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 2033 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-12-05 Chinese
关于子公司收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving an approval notice from the National Medical Products Administration for the listing application of a chemical raw material drug. It contains no financial statements or detailed financial data, but rather regulatory approval information and risk disclosures. The document is short (939 characters) and serves as a formal announcement of a regulatory approval event. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2025-11-11 Chinese
关于子公司收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving an approval notice from the National Medical Products Administration for the listing of a chemical raw material drug. It contains no financial statements or detailed financial data, nor is it a report or presentation. The document is a regulatory announcement about a product approval, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not related to management changes, voting results, or capital changes. Given the nature of the content and the absence of financial data, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-11-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.